Radiopharm (RADX) outlined a broad radiopharmaceutical pipeline and several near-term clinical milestones at the Deutsche Bank Virtual Investor Conference on Thursday, 12 November 2026, according to Investing.com. The company said it has two diagnostic programs and four therapeutic programs, all aimed at oncology targets.
Management said the FDA aligned with a plan for RAD101 to move ahead with a single phase III study rather than the usual two. The company said this could cut time and cost by about 50%. The phase III trial is expected to enroll about 280 patients, with sensitivity and specificity endpoints expected by year-end 2024. The program targets patients with non-brain metastases who face suspected but unproven relapse after stereotactic radiation therapy.
For RAD202, a HER2-targeted nanobody radiotherapy, the company said dose levels 1 through 3 were completed with no dose-limiting toxicities. Management said one patient had a tumor size change of 0% to -11%, and it reported no serious adverse events, no grade 4 or 5 events, and five total grade 3 treatment-emergent adverse events.
For RAD204, a PD-L1-targeted program, management said the dose level 3 patients had a 50% response rate and a median progression-free survival of 6.7 months. Management said the data suggest the program may compare favorably with standard of care, though it remains early.
The company said it plans to keep investing in its four therapeutic programs while seeking partners for its diagnostic assets, including RAD301, which completed a phase I study. Management pointed to 2027 as a year with multiple catalysts, including dose-escalation updates and possible moves into phase II dosing. No financial results or revenue figures were discussed.
Shares traded at $0.77 on the day, down 7.23% from the previous close of $0.82, according to the report. The report also cited a market capitalization of $11.81 million and a 52-week range of $0.736 to $16.25.